FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1606085389> ?p ?o ?g. }

• W1606085389 endingPage "333" @default.
• W1606085389 startingPage "307" @default.
• W1606085389 abstract "Lupus nephritis (LN) is a major cause of morbility and mortality in patients with systemic lupus erythematosus (SLE). Similarly, kidney involvement is common in SLE, occurring in up to 60% of affected adults during the course of their disease. Recently, the classification of glomerulonephritis in SLE has been modified; in this classification, it was proposed that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving < 50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving = 50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivions for active and sclerotic lesions; class V for membranous glomerulonephritis; and class VI for advanced sclerotic lesions. It is important that combinations of membranous and proliferative glomerulonephritis should be reported individually in the diagnosis line, as well as the diagnosis should also include notations for any concomitant vascular or tubolointersticial lesions, therefore, one of the main advantages of this classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and giving a basis for further clinicopathologic studies. Otherwise, despite the development of new modalities of treatment in LN, cyclophosphamide remains the preferred initial treatment for severe forms of LN like proliferative and membranous glomerulonephritis associated with both, lesions of class III or class IV; nevertheless, the optimal treatment remains challenging because of the adverse effects associated with cyclophosphamide like sustained amenorrhea, infertility, increased susceptibility to infection, bone marrow suppression, hemorrhagic cystitis, and malignancy. Finally, due to these adverse effects new alternative approaches to the treatment of LN are desirable and also for some patients who fail to achieve remission with standar cytotoxic therapy and for who relapse when therapy is reduced. For refractory disease, new immunosuppressive and immunomodulating agents, immunoablative high dose of cyclophosphamide, apheresis and the biological response modifiers can be consider." @default.
• W1606085389 created "2016-06-24" @default.
• W1606085389 creator A5012419801 @default.
• W1606085389 creator A5019847195 @default.
• W1606085389 creator A5067250236 @default.
• W1606085389 creator A5081994670 @default.
• W1606085389 date "2006-12-01" @default.
• W1606085389 modified "2023-09-26" @default.
• W1606085389 title "Nefropatía lúpica. Presentación clínica, clasificación y tratamiento" @default.
• W1606085389 cites W109151247 @default.
• W1606085389 cites W130788070 @default.
• W1606085389 cites W1498233434 @default.
• W1606085389 cites W1535965224 @default.
• W1606085389 cites W154508931 @default.
• W1606085389 cites W1583161633 @default.
• W1606085389 cites W1590683261 @default.
• W1606085389 cites W1949176576 @default.
• W1606085389 cites W196227857 @default.
• W1606085389 cites W1965062568 @default.
• W1606085389 cites W1966613111 @default.
• W1606085389 cites W1970650350 @default.
• W1606085389 cites W1971058219 @default.
• W1606085389 cites W1974536493 @default.
• W1606085389 cites W1974637546 @default.
• W1606085389 cites W1976588005 @default.
• W1606085389 cites W1985224808 @default.
• W1606085389 cites W1990536034 @default.
• W1606085389 cites W1991756636 @default.
• W1606085389 cites W1993619587 @default.
• W1606085389 cites W1995752760 @default.
• W1606085389 cites W1997199608 @default.
• W1606085389 cites W2004632147 @default.
• W1606085389 cites W2005010938 @default.
• W1606085389 cites W2015779401 @default.
• W1606085389 cites W2016497158 @default.
• W1606085389 cites W2017709470 @default.
• W1606085389 cites W2023637057 @default.
• W1606085389 cites W2025529696 @default.
• W1606085389 cites W2025724624 @default.
• W1606085389 cites W2027077460 @default.
• W1606085389 cites W2027902571 @default.
• W1606085389 cites W2030437282 @default.
• W1606085389 cites W2035435135 @default.
• W1606085389 cites W2041530579 @default.
• W1606085389 cites W2045139782 @default.
• W1606085389 cites W2046325445 @default.
• W1606085389 cites W2046468905 @default.
• W1606085389 cites W2049142512 @default.
• W1606085389 cites W2059856860 @default.
• W1606085389 cites W2060041600 @default.
• W1606085389 cites W2062269863 @default.
• W1606085389 cites W2064213103 @default.
• W1606085389 cites W2065168884 @default.
• W1606085389 cites W2066137380 @default.
• W1606085389 cites W2077293946 @default.
• W1606085389 cites W2078923057 @default.
• W1606085389 cites W2079622420 @default.
• W1606085389 cites W2079694951 @default.
• W1606085389 cites W208064927 @default.
• W1606085389 cites W2083111843 @default.
• W1606085389 cites W2084109190 @default.
• W1606085389 cites W2085197333 @default.
• W1606085389 cites W2086059540 @default.
• W1606085389 cites W2086306003 @default.
• W1606085389 cites W2088340307 @default.
• W1606085389 cites W2089016290 @default.
• W1606085389 cites W2090075306 @default.
• W1606085389 cites W2090469286 @default.
• W1606085389 cites W2094074845 @default.
• W1606085389 cites W2096194879 @default.
• W1606085389 cites W2096600732 @default.
• W1606085389 cites W2099338332 @default.
• W1606085389 cites W2102435584 @default.
• W1606085389 cites W2107871522 @default.
• W1606085389 cites W2108202477 @default.
• W1606085389 cites W2110185829 @default.
• W1606085389 cites W2114380142 @default.
• W1606085389 cites W2119676645 @default.
• W1606085389 cites W2121956201 @default.
• W1606085389 cites W2124170783 @default.
• W1606085389 cites W2126746651 @default.
• W1606085389 cites W2132284224 @default.
• W1606085389 cites W2135212798 @default.
• W1606085389 cites W2135503440 @default.
• W1606085389 cites W2145552180 @default.
• W1606085389 cites W2146203649 @default.
• W1606085389 cites W2147981739 @default.
• W1606085389 cites W2149930918 @default.
• W1606085389 cites W2153415288 @default.
• W1606085389 cites W2156597637 @default.
• W1606085389 cites W2160388191 @default.
• W1606085389 cites W2164428548 @default.
• W1606085389 cites W2168495534 @default.
• W1606085389 cites W224586676 @default.
• W1606085389 cites W2321889993 @default.
• W1606085389 cites W2325870812 @default.
• W1606085389 cites W2332578109 @default.
• W1606085389 cites W2412733529 @default.

• next